Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
91 hedge funds and large institutions have $364M invested in Generation Bio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 11 closing their positions.
11,000% more call options, than puts
Call options by funds: $111K | Put options by funds: $1K
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
3% more funds holding
Funds holding: 88 → 91 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.21% less ownership
Funds ownership: 9.91% → 9.7% (-0.21%)
13% less capital invested
Capital invested by funds: $416M → $364M (-$52.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.4M |
| 2 |
BlackRock
New York
|
+$2.18M |
| 3 |
Renaissance Technologies
New York
|
+$1.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.1M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$914K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$9.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.75M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$8.15M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.94M |
| 5 |
Two Sigma Investments
New York
|
-$673K |
GBIO Hedge Fund Activity: Q2 2022 in Review
91 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2022, worth a combined $364M — down 13% from $416M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GBIO positions and 11 closed out — a net gain of 6 holders — while 35 added to existing stakes and 24 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $14.4M. The largest seller was Casdin Capital, exiting entirely with an estimated $9.72M sold.
- 91 institutional investors held Generation Bio (GBIO) as of Q2 2022, up from 88 in Q1 2022.
- Funds reported $364M of Generation Bio stock for Q2 2022, down 13% quarter-over-quarter.
- 17 funds opened new Generation Bio positions in Q2 2022 and 11 closed out, a net change of +6 holders.
- The largest Generation Bio buyer in Q2 2022 was PFM Health Sciences, an estimated $14.4M added.
- The largest Generation Bio seller in Q2 2022 was Casdin Capital, an estimated $9.72M sold.
Based on aggregated 13F filings for Q2 2022.